Welcome to our dedicated page for Cleartronic news (Ticker: CLRI), a resource for investors and traders seeking the latest updates and insights on Cleartronic stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cleartronic's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cleartronic's position in the market.
Cleartronic, Inc. (CLRI) reported a strong financial performance for 2020, showcasing a 50% increase in revenue compared to the previous year, driven largely by growth in its ReadyOp/ReadyMed software platform. Operating expenses declined by approximately 10%, reflecting improved operational efficiencies. The company achieved an income from continuing operations of $230,205, a significant recovery from a loss of $72,051 in 2019. EBITDA surged to $250,412, highlighting a remarkable 1,214% increase year-over-year. CEO Marc Moore expressed optimism about future growth opportunities.